In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e17614-e17614
Abstract:
e17614 Background: Compared with western countries, the application time of PARP inhibitor in China is shorter and the real world outcomes are affected by many factors. The objective of this study was to present the real-world patients’ portrait, and the results of Niraparib treatment in China. Methods: This study included 142 patients treated with Niraparib from 8 hospitals in China between Dec. 2018 and Sep. 2021. Patients’ characteristics were summarized. The efficacy and safety in first-line maintenance (1L-M), platinum-sensitive recurrence maintenance (PSR-M), and treatment for ovarian cancer were evaluated. Survival outcomes and the factors influencing PFS were estimated. Results: 93 patients received Niraparib as 1L-M, 31 as PSR-M and 18 as salvage. BRCA status was wild-type or unknown in 87.3% of patients. With a median follow-up time of 8.7m, the mPFS for 1L-M has not yet been reached, and the mPFS for PSR-M and salvage therapy was 10.5 months (95%CI: 3.9-NE) and 5.7 months (95%CI: 3.0-13.0), respectively. Responses to last chemotherapy (CR vs. PR, P= 0.0077) and CA125 value before taking Niraparib (≤35UI/ml vs. 〉 35UI/ml, P= 0.0344) were two important factors affecting PFS among 1L and PSR patients. 12.7%(18/142) of patients experienced grade ≥3 hematologic adverse events and 23.2% experienced dose adjustment. It was noteworthy that when the interval of chemotherapy and Niraparib 〈 21 days, the incidence of Grade ≥ 3 adverse events increased significantly ( P= 0.0355). Conclusions: This was the first and largest observational multicenter study reporting the outcomes of Niraparib treatment for ovarian cancer in real-world setting in China. Generally, Niraparib was effective and well tolerated, which was consistent with the results of prospective trials. However, in real world, it was more inclined to use Niraparib in late-line treatment without genetic testing.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2022.40.16_suppl.e17614
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2022
detail.hit.zdb_id:
2005181-5
